Recommendation of the President – Bellix (bilastine)
On 30 April 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 52/2025 on the appraisal of drug Bellix (bilastine) for the indication: symptomatic treatment of allergic rhinitis and conjunctivitis (seasonal and perennial) and urticaria in adults and adolescents (aged 12 years and older).